The trial you posted about is sponsored by MSKCC; the drug in question is GSK’s Jemperli, which is a PD-1 inhibitor similar to Opdivo and Keytruda. Jemperli was approved by the FDA in 2021.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.